ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +4.3% ·
aandelenstroom +0.3% ·
netto nieuwe posities 0.0%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 187.62K | $45.53M | n/a | −2 |
| Q2 2026 | 160 | +3 | 106.88M | $32.15B | +7 | −5 |
| Q1 2026 | 161 | -2 | 108.78M | $35.89B | +4 | −7 |
| Q4 2025 | 162 | -2 | 118.83M | $47.26B | +1 | −2 |
| Q3 2025 | 24 | +1 | 85.59M | $39.02B | +2 | −2 |
| Q2 2025 | 21 | -1 | 76.99M | $25.10B | n/a | −1 |
| Q1 2025 | 19 | +2 | 40.24M | $10.86B | +3 | −1 |
| Q4 2024 | 17 | 0 | 41.95M | $9.87B | n/a | n/a |
| Q3 2024 | 16 | +1 | 39.28M | $10.80B | +2 | −1 |
| Q2 2024 | 15 | n/a | 40.30M | $9.79B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 16.77M | +6.1% | $7.65B | 0.4% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | Capital World Investors ✦ | 16.43M | -2.2% | $7.49B | 1.0% | ▼ Trim | 6 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passief) | 13.57M | +2.0% | $6.19B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 4 | BlackRock ✦ (passief) | 9.90M | -0.8% | $4.52B | 0.1% | ▼ Trim | 2 | SEC ↗ ×22 |
| 5 | JPMorgan Chase ✦ | 9.09M | n/a | $4.14B | 0.1% | n/c | 1 | SEC ↗ ×40 |
| 6 | State Street Global Advisors ✦ (passief) | 3.08M | -2.9% | $1.41B | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 2.79M | -8.0% | $1.27B | 0.9% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | Geode Capital Management ✦ (passief) | 2.50M | +4.2% | $1.14B | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Dodge & Cox ✦ | 2.32M | -27.4% | $1.06B | 0.6% | ▼ Trim | 6 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.83M | -12.0% | $832.80M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 11 | T. Rowe Price ✦ | 1.80M | -42.8% | $820.93M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Arrowstreet Capital ✦ | 1.36M | +698.8% | $618.16M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 744.01K | +295.2% | $336.01M | 0.2% | ▲ Add | 6 | SEC ↗ ×8 |
| 14 | Morgan Stanley ✦ | 726.06K | n/a | $331.09M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 15 | Two Sigma Investments ✦ | 595.93K | +73.6% | $271.74M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 16 | Millennium Management ✦ | 549.93K | +508.0% | $250.77M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 17 | Goldman Sachs Group ✦ | 538.35K | n/a | $245.49M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 18 | Marshall Wace ✦ | 508.37K | +113.1% | $231.82M | 0.3% | ▲ Add | 5 | SEC ↗ ×3 |
| 19 | Citadel Advisors ✦ | 221.84K | -63.1% | $101.16M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | D. E. Shaw & Co. ✦ | 199.42K | +84.2% | $90.93M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 33.91K | Nieuw | $15.46M | 0.1% | New | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 28.14K | +58.2% | $12.83M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 23 | Point72 Asset Management ✦ | 6.20K | -96.9% | $2.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Soros Fund Management ✦ | 4.29K | Nieuw | $1.96M | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $15.46M | 0.1% |
| Soros Fund Management | $1.96M | 0.0% |
Verlaten
| Norges Bank | $662.84M | was 0.1% |
| Adage Capital Partners | $27.52M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 781 houders, 122.25M aandelen, $37.95B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 1.76K aand · $398,855
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie